Price
$4.2
Increased by +0.00%
Dollar Volume (20D)
324.21 K
ADR%
8.16
Earnings Report Date (estimate)
Aug 11, 23 (-0.85)
Market Cap.
68.66 M
Shares Float
9.32 M
Shares Outstanding
16.35 M
Beta
1.83
Price / Earnings
-1.00
BPR
365.37
20D Range
3.59 4.69
50D Range
2.35 4.69
200D Range
1.70 4.75
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Apr 28, 23 -1.29
Decreased by -35.79%
-4.05
Increased by +16.83%
Mar 24, 23 -1.04
Decreased by -30.00%
-0.89
Decreased by -18.94%
Oct 28, 22 -0.80
Decreased by -33.33%
-0.95
Increased by +16.62%
Aug 12, 22 -0.95
Decreased by -171.43%
-0.60
Decreased by -97.22%
Apr 27, 22 -0.95
Decreased by -46.15%
-0.52
Decreased by -159.02%
Mar 25, 22 -0.80
Increased by +78.67%
-0.72
Decreased by -15.43%
Oct 26, 21 -0.60
Decreased by -20.00%
-0.65
Increased by +11.83%
Aug 6, 21 -0.35
Increased by +86.00%
-0.55
Increased by +66.12%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 0.00
Decreased by N/A%
-19.11 M
Decreased by -48.19%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-14.48 M
Decreased by -69.28%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-10.93 M
Decreased by -101.32%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-12.89 M
Decreased by -295.32%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-12.90 M
Decreased by -225.75%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-8.55 M
Decreased by -64.98%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-5.43 M
Increased by +31.55%
Decreased by N/A%
Decreased by N/A%
Sep 30, 20 0.00
Decreased by N/A%
-3.26 M
Increased by +70.94%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.